Company intelligence / Profile preview

MEBSTER

Ownership: Private
Development stage: Commercial

Overview

MEBSTER develops and commercializes the UNILEXA Exoskeleton, a wearable robotic device designed to help individuals with lower limb paralysis or spinal cord injuries regain mobility. Clinical use has shown improvements in patient independence, stability, and quality of life. The company collaborates with leading rehabilitation centers and participates in international conferences focused on spinal cord injury research.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (exoskeleton for rehabilitation)
Industry: Assistive Medical Devices

Drug pipeline

2 assets

UNILEXA Prime

Commercial

Indications: Spinal cord injury

1 more asset in the full pipeline.

Request access →

Partnerships

Royal Health GroupStátní léčebné lázně Janské Lázně spa hospital/rehabilitation center

Beyond the preview

Go deeper on MEBSTER.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEBSTER.

Explore the full profile